ReviewOpen forum infectious diseases2021
Harnessing the Potential of Multiomics Studies for Precision Medicine in Infectious Disease.
Review in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Multiomics characterization of acute child illness and mortality in Africa and South Asia.Nature communications · 2026Article
- Host Proteome Remodeling During Group A Streptococcus Skin Infection.Molecular & cellular proteomics : MCP · 2026Article
- The Changing Paradigm in Infectious Diseases-Host-Directed Medicine: Implications for the Next Generation of ID Physicians.The Journal of infectious diseases · 2026Article
- Advances in Spatial Transcriptomics for Infectious Disease Research: Insight for Vaccine Development.Vaccines · 2026Review
- Comparative Evaluation of Sequencing Technologies for Detecting Antimicrobial Resistance in Bloodstream Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Observational
- Genetic liability for anxiety and treatment response to the monoamine stabilizer OSU6162 in alcohol dependence: a retrospective secondary analysis.Pharmacological reports : PR · 2025Article
- Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches.International journal of molecular sciences · 2025Review
- Cytokine-Based Insights into Bloodstream Infections and Bacterial Gram Typing in ICU COVID-19 Patients.Metabolites · 2025Article
- Joint fluid multi-omics improves diagnostic confidence during evaluation of children with presumed septic arthritis.Pediatric rheumatology online journal · 2025Article
- PepSeq as a highly multiplexed platform for melioidosis antigen discovery and vaccine development.Frontiers in immunology · 2025Article
- A Critical Review of the Prospect of Integrating Artificial Intelligence in Infectious Disease Diagnosis and Prognosis.Interdisciplinary perspectives on infectious diseases · 2025Review
- Molecular mechanisms of neutrophil regulatory network in anti-Candida infection.Frontiers in immunology · 2025Review
- Conventional and unconventional T-cell responses contribute to the prediction of clinical outcome and causative bacterial pathogen in sepsis patients.Clinical and experimental immunology · 2024Article
- [Precision medicine in infectious diseases].Innere Medizin (Heidelberg, Germany) · 2024Review
- Future applications of host direct therapies for infectious disease treatment.Frontiers in immunology · 2024Review
- Opportunities and challenges of 5G network technology toward precision medicine.Clinical and translational science · 2023Review
- Disrupting the infectious disease ecosystem in the digital precision health era innovations and converging emerging technologies.Antimicrobial agents and chemotherapy · 2023Article
- Epidemiology and antifungal susceptibilities of clinically isolatedEpidemiology and infection · 2023Article
- Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study.Pharmacological reports : PR · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 1 country.
Funding
Abstract
The field of infectious diseases currently takes a reactive approach and treats infections as they present in patients. Although certain populations are known to be at greater risk of developing infection (eg, immunocompromised), we lack a systems approach to define the true risk of future infection for a patient. Guided by impressive gains in "omics" technologies, future strategies to infectious diseases should take a precision approach to infection through identification of patients at intermediate and high-risk of infection and deploy targeted preventative measures (ie, prophylaxis). The advances of high-throughput immune profiling by multiomics approaches (ie, transcriptomics, epigenomics, metabolomics, proteomics) hold the promise to identify patients at increased risk of infection and enable risk-stratifying approaches to be applied in the clinic. Integration of patient-specific data using machine learning improves the effectiveness of prediction, providing the necessary technologies needed to propel the field of infectious diseases medicine into the era of personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.